Skip to main content
. 2022 Apr 15;23(6):181. doi: 10.3892/ol.2022.13301

Table II.

Chemotherapy and immunotherapy for STK11 mutation status in NSCL.

OS (month) PFS (month)


Variable STK11m STK11wt STK11m STK11wt
Chemotherapy (130)
  First-line 11.7 18.9 4.5 6.1
  Second-line 13.1 15.2 4.2 4.5
Immunotherapy (131)
  First-line 14.2 20.1 4.1 5.4
  Second-line 6.6 13.6 2.2 3.1

NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; STK11, serine/threonine kinase 11; STK11m, STK11 mutation; STK11wt, STK11 wild-type.